EV/EBITDA - Dizal Jiangsu Pharmaceutical Co Ltd (SSE:688192) - Alpha Spread
D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 33.4 CNY -7.2%
Market Cap: 13.6B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-13
Current
-15.4
Median
5.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-13
=
Enterprise Value
14.3B CNY
/
EBITDA
-1.1B CNY
All Countries
Close

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-13.1
2-Years Forward
EV/EBITDA
-22.9
3-Years Forward
EV/EBITDA
N/A

See Also

Discover More